Guidelines on the investigation and management of antiphospholipid syndrome

作者：Deepa J. Arachchillage, Sean Platton, Kieron Hickey, Justin Chu, Matthew C. Pickering, Peter Sommerville, Peter MacCallum, Karen Breen · 发表于：British Journal of Haematology · 年份：2024 · DOI：10.1111/bjh.19635 · 被引用次数：53 · 研究领域：Systemic Lupus Erythematosus Research、Peripheral Neuropathies and Disorders、Liver Diseases and Immunity

This guideline was compiled according to the British Society for Haematology (BSH) process at (https://b-s-h.org.uk/media/16732/bsh-guidance-development-process-dec-5-18.pdf). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate the levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http://www.gradeworkinggroup.org. A literature search was carried out using the terms given in the appendix up to April 2024. Review of the guideline followed the standard BSH guidelines procedure. Following review of the draft guideline by the BSH Haemostasis and Thrombosis Task Force and the BSH Guidelines Committee, it was placed on the members' section of the BSH website for comment (sounding board) and these comments were addressed and incorporated appropriately. The guideline was reviewed by the Royal College of Obstetricians and Gynaecologists, Thrombosis UK and APS Support UK. These organizations do not necessarily approve or endorse the contents. This guidance updates and replaces previous BSH guidelines.1, 2 Antiphospholipid syndrome (APS) is an autoimmune disease characterised by thrombosis (venous, arterial and/or microvascular) and/or pregnancy morbidity in association with persistently positive antiphospholipid antibodies (aPL). APS can occur in isolation (primary APS) or in association with other autoimmune diseases, most commonly systemic lupus erythematosus (SLE) and rheuma...